CD274 and non-small cell lung carcinoma: In addition to these markers, it is important to evaluate the immunohistochemical expression of programmed death ligand 1 (PD-L1), as PD-L1 expression is a confirmed predictive factor for the treatment outcome of ICI monotherapy in NSCLC patients.